Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

In its latest and biggest fundraising to date, Moximed has bagged $50m in a series C round, which will help the company take its joint-unloading technology for osteoarthritis patients through US approval and into early commercialization.

New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.